4-(hexan-2-yl)pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(hexan-2-yl)pyridine
• 英文别名: 4-Hexan-2-ylpyridine
• 化学式: C₁₁H₁₇N
• 分子量: 163.263
• InChiKey: HICVUYBLFSKRAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-Pyridin-4-yl-hexan-2-ol 在 samarium diiodide 、 三甲基乙酸 作用下， 以 四氢呋喃 、 六甲基磷酰三胺 为溶剂， 反应 0.17h， 以62%的产率得到4-(hexan-2-yl)pyridine
  参考文献：
  名称：

  二碘化sa还原吡啶甲醇的新方法

  摘要：

  描述了通过SmI 2介导的吡啶甲醇衍生物的脱氧有效合成烷基吡啶衍生物。

  DOI：

  10.1016/s0040-4039(99)01852-3

文献信息

• Transition-Metal-Free BF₃-Mediated Oxidative and Non-Oxidative Cross-Coupling of Pyridines
  作者：Quan Chen、Thierry León、Paul Knochel

  DOI：10.1002/anie.201400750

  日期：2014.8.11

  We report a BF3‐mediated direct alkynylation of pyridines at C(2) by using a variety of alkynyllithium reagents (oxidative cross‐coupling). Moreover, we have developed a novel transition‐metal‐free cross‐coupling method between alkylmagnesium reagents and 4‐substituted pyridines, such as isonicotinonitrile and 4‐chloropyridine, by employing BF3⋅OEt2 as a promoter. The combination of these methods enabled

  我们报告了BF 3介导的吡啶在C（2）上通过使用各种炔基锂试剂（氧化交叉偶联）的直接烷基化。此外，我们通过使用BF 3 OEt 2作为促进剂，在烷基镁试剂与4-取代的吡啶（例如异烟腈和4-氯吡啶）之间开发了一种新型的无过渡金属的交叉偶联方法。这些方法的结合使我们能够有效地制备各种二，三和四取代的吡啶。
• Compositions and methods for treating tuberculosis
  申请人：The Broad Institute, Inc.

  公开号：US10329257B2

  公开（公告）日：2019-06-25

  The present invention provides compounds for the treatment of a bacterial infection. Additionally, the present invention provides compositions and methods for using these compounds and compositions in the treatment of a bacterial infection in a subject.

  本发明提供了用于治疗细菌感染的化合物。此外，本发明还提供了使用这些化合物和组合物治疗受试者细菌感染的组合物和方法。
• Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the Human Immunodeficiency Virus
  申请人：YALE UNIVERSITY

  公开号：US11136316B2

  公开（公告）日：2021-10-05

  The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-HI's, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-HI's bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein.

  本发明涉及治疗艾滋病毒感染的新型双功能化合物和方法。这种双功能小分子一般称为 ARM-HI，通过正交途径发挥作用，抑制 gp120 与 CD4 的相互作用，并将抗 DNP 抗体募集到表达 gp120 的细胞，从而防止细胞感染和 HIV 的传播。研究表明，ARM-HI 与 CD4 竞争性地结合到 gp120 和表达 gp-120 的细胞上，从而降低病毒的感染性，如 MT-2 细胞试验所示，这种结合通过招募抗 DNP 抗体与之结合而形成三元复合物，存在于三元复合物中的抗体可促进依赖补体的 gp120 表达细胞的破坏。本文描述了化合物和方法。
• Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor
  申请人：Corvus Pharmaceuticals, Inc.

  公开号：US11254686B1

  公开（公告）日：2022-02-22

  Disclosed herein, inter alia, are certain substituted thieno[3,2-b]pyrimidine compositions and methods for modulating Adenosine Receptors, for example, having the formula:

  本文特别披露了用于调节腺苷受体的某些取代的噻吩并[3,2-b]嘧啶组合物和方法，例如，具有以下式子的组合物和方法：
• BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS
  申请人：YALE UNIVERSITY

  公开号：US20200392121A1

  公开（公告）日：2020-12-17

  The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-HI's, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-HI's bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein.